AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31545113 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31545689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose and volume of radiotherapy (RT) - 30.6 Gy whole ventricular field and 54 Gy tumor-bed boost
Number of subjects: 107
Study 31545689 — intervention group
Group type: COMPARATOR
Intervention: Full-dose craniospinal irradiation - 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost (used in ACNS0122)
Number of subjects: 107
Study 31548190 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted fat mass
Number of subjects: 10251
Study 31548190 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted lean body mass
Number of subjects: 10251
Study 31548247 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic 670G hybrid closed-loop system (Auto Mode)
Number of subjects: 79
Study 31548342 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC (PET Response Criteria)
Number of subjects: 81
Study 31548342 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST (Response Evaluation Criteria in Solid Tumors)
Number of subjects: 81
Study 31548342 — intervention group
Group type: EXPERIMENTAL
Intervention: PRC and RECIST
Number of subjects: 81
Study 31548396 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP)
Number of subjects: 0
Study 31548621 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment based on absolute cardiovascular risk
Number of subjects: 0
Study 31548621 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 31548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant messaging for a social media campaign targeting tobacco cessation during pregnancy.
Number of subjects: 112
Study 31548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative focus groups and individual interviews (Round 1)
Number of subjects: 112
Study 31548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative survey interviews (Round 2)
Number of subjects: 112
Study 31548863 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to manage stress and promote healthy pregnancy targets (e.g., prenatal care)
Number of subjects: 112
Study 31549001 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB Prompt mobile application
Number of subjects: 10
Study 31549001 — intervention group
Group type: COMPARATOR
Intervention: Standard HBB training without app access
Number of subjects: 10
Study 31549155 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg oral dose of primaquine (PQ)
Number of subjects: 550
Study 31549155 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6 genotypes
Number of subjects: 550
Study 31549262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding risk scores (PARIS, PRECISE-DAPT, BleeMACS)
Number of subjects: 346
Study 31549262 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty scales (Short Physical Performance Battery, Columbia, Edmonton, Clinical Frailty Scale)
Number of subjects: 346
Study 31549262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bleeding risk scores and frailty scales
Number of subjects: 346
Study 31549262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding risk scores and frailty scales
Number of subjects: 346
Study 31549312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU/kg N9-GP
Number of subjects: 0
Study 31549578 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated data relay intervention during a 6-month phase.
Number of subjects: 2171
Study 31549578 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated data relay intervention
Number of subjects: 2171
Study 31549578 — intervention group
Group type: COMPARATOR
Intervention: Phase A (status quo)
Number of subjects: 2171
Study 31550265 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI quartiles (higher BMI)
Number of subjects: 5964
Study 31550265 — intervention group
Group type: EXPERIMENTAL
Intervention: WHtR quartiles (higher WHtR)
Number of subjects: 5964
Study 31550265 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean-fat group (low BMI <24.5 kg/m2 and high WHtR ≥0.55)
Number of subjects: 5964
Study 31550265 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF and HFrEF subtypes
Number of subjects: 5964
Study 31550715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring of guide-wire introduction during dialysis catheter insertion
Number of subjects: 30
Study 31550737 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100
Study 31550737 — intervention group
Group type: COMPARATOR
Intervention: Wait and scan
Number of subjects: 100
Study 31550737 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH-mutated glioma
Number of subjects: 100
Study 31550737 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscellaneous rare LGGs
Number of subjects: 100
Study 31550737 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH wild-type WHO grade II or III glioma
Number of subjects: 100
Study 31551193 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to 50 mg or 100 mg as needed.
Number of subjects: 133
Study 31551193 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to maintain T trough levels.
Number of subjects: 133
Study 31551283 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive proportional assist ventilation (PAV)
Number of subjects: 15
Study 31551283 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (PSV)
Number of subjects: 15
Study 31551349 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg OXi4503
Number of subjects: 2
Study 31551349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg OXi4503
Number of subjects: 2
Study 31551349 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg OXi4503
Number of subjects: 2
Study 31551349 — intervention group
Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 2
Study 31551376 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV Treatment as Prevention (TasP) in Tayside, Scotland
Number of subjects: 500
Study 31551376 — intervention group
Group type: COMPARATOR
Intervention: Control sites in Scotland and England
Number of subjects: 500
Study 31551805 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term high-intensity interval training (HIIT)
Number of subjects: 147
Study 31551805 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term physical activity (PA)
Number of subjects: 147
Study 31551805 — intervention group
Group type: COMPARATOR
Intervention: Healthy active (HA)
Number of subjects: 147
Study 31551824 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 39
Study 31551824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 31551902 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional management (MM) including psychoeducation and cognitive rehabilitation, n=34
Number of subjects: 221
Study 31551902 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific treatment other than psychoeducation, n=46
Number of subjects: 221
Study 31551902 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable outcome (FO) group, n=101
Number of subjects: 221
Study 31552171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Pembrolizumab
Number of subjects: 0
Study 31552171 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31552422 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices for identifying and accounting for regression to the mean (RTM) in nutrition and obesity research
Number of subjects: 0
Study 31552422 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods to quantify the degree of RTM
Number of subjects: 0
Study 31552543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.07%
Number of subjects: 49
Study 31552543 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.3%
Number of subjects: 49
Study 31552588 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 1-10 brain metastases (BM) before radiosurgery
Number of subjects: 92
Study 31552588 — intervention group
Group type: COMPARATOR
Intervention: Controls (N=104)
Number of subjects: 92
Study 31552641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50-mg tablet once daily for 24 weeks
Number of subjects: 97
Study 31552721 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (lowest concentration causing 5 coughs or more, C5)
Number of subjects: 1882
Study 31552721 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 1882
Study 31552762 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of oligomeric α-Synuclein in reflex tears
Number of subjects: 0
Study 31552762 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 31553054 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based dosing of avelumab (10 mg/kg)
Number of subjects: 1827
Study 31553054 — intervention group
Group type: COMPARATOR
Intervention: Flat dosing of avelumab (800 mg every 2 weeks)
Number of subjects: 1827
Study 31553205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 120
Study 31553429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DO body composition accuracy to DXA
Number of subjects: 407
Study 31553429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DO body fat test-retest precision
Number of subjects: 407
Study 31553429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DO visceral fat precision
Number of subjects: 407
Study 31553429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DO PCs correlation with serum markers
Number of subjects: 407
Study 31553429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DO PCs prediction of isometric knee strength
Number of subjects: 407
Study 31553487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib at 50 mg daily
Number of subjects: 83
Study 31553501 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance (self-reported poor or restless sleep)
Number of subjects: 319
Study 31553639 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with three cycles of cisplatin.
Number of subjects: 111
Study 31553639 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with two cycles of cisplatin (amended treatment).
Number of subjects: 111
Study 31553639 — intervention group
Group type: COMPARATOR
Intervention: Three cycles of cisplatin during CCR.
Number of subjects: 111
Study 31553940 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral caudate nucleus deep brain stimulation (DBS)
Number of subjects: 6
Study 31554502 — intervention group
Group type: EXPERIMENTAL
Intervention: Good collateral status on mCTA
Number of subjects: 65
Study 31554502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate collateral status on mCTA
Number of subjects: 65
Study 31554502 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor collateral status on mCTA
Number of subjects: 65
Study 31555109 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal; F3, cathodal, Fp2, 2A, 20 min) twice daily for five consecutive days
Number of subjects: 20
Study 31555109 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 20
Study 31555382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-FAR group (FAR > 8.713)
Number of subjects: 1352
Study 31555382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen-to-albumin ratio (FAR)
Number of subjects: 1352
Study 31555382 — intervention group
Group type: COMPARATOR
Intervention: Low-FAR group (FAR ≤ 8.713)
Number of subjects: 1352
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 12012
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: (Neo) adjuvant chemotherapy
Number of subjects: 12012
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 12012
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormonotherapy
Number of subjects: 12012
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life, psychological and behavioral outcomes
Number of subjects: 12012
Study 31555487 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic sub-studies
Number of subjects: 12012
Study 31555522 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg per day)
Number of subjects: 187
Study 31555522 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 187
Study 31555714 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Number of subjects: 41
Study 31555714 — intervention group
Group type: COMPARATOR
Intervention: Autologous chondrocyte implantation (ACI-C)
Number of subjects: 41
Study 31555795 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 34
Study 31555795 — intervention group
Group type: COMPARATOR
Intervention: N/A (comparison with control group HT)
Number of subjects: 34
Study 31555815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration and quality measured using a wrist-worn accelerometer and Pittsburgh Sleep Quality Index
Number of subjects: 118
Study 31555815 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cold exposure to determine BAT volume, activity, and radiodensity
Number of subjects: 118
Study 31556242 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 29
Study 31556242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 29
Study 31556242 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) and Sleeve gastrectomy (SG)
Number of subjects: 29
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test A
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test B
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test F
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test C
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test E
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test D
Number of subjects: 0
Study 31556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pregnancy test G
Number of subjects: 0
Study 31557279 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease participants
Number of subjects: 15
Study 31557279 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 15
Study 31557355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous Candida albicans antigen in participants with polyneuropathy
Number of subjects: 41
Study 31557355 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous Candida albicans antigen in healthy controls
Number of subjects: 41
Study 31557355 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous Candida albicans antigen in participants without polyneuropathy
Number of subjects: 41
Study 31557355 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 41
Study 31557423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in men at the operated knee
Number of subjects: 272
Study 31557423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in women at the operated knee
Number of subjects: 272
Study 31557423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in obese men at the operated knee
Number of subjects: 272
Study 31557423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in women at the nonoperated knee
Number of subjects: 272
Study 31557423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in obese women
Number of subjects: 272
Study 31557500 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to major roadways (within 100 m)
Number of subjects: 350
Study 31557500 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximity to major roadways (greater than 100 m)
Number of subjects: 350
Study 31558250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 31558366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega-3 fatty acids
Number of subjects: 269
Study 31558366 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention alone
Number of subjects: 269
Study 31558366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 31558424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once a day for 7 to 21 days preoperatively, resumed postoperatively in 28-day cycles.
Number of subjects: 5
Study 31558424 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (preoperative and postoperative administration).
Number of subjects: 5
Study 31558447 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Somatic Symptom Scale-China (SSS-CN) questionnaire
Number of subjects: 852
Study 31558467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab (NHL: 900 mg; CLL: 600 or 900 mg) + Umbralisib (800 or 1200 mg)
Number of subjects: 0
Study 31558467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ublituximab + Umbralisib
Number of subjects: 0
Study 31558469 — intervention group
Group type: EXPERIMENTAL
Intervention: GSI treatment
Number of subjects: 0
Study 31558469 — intervention group
Group type: EXPERIMENTAL
Intervention: GSI treatment in MM tumor-bearing NOD/SCID/γc-/- mice
Number of subjects: 0
Study 31558469 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term GSI administration to MM patients
Number of subjects: 0
Study 31558479 — intervention group
Group type: EXPERIMENTAL
Intervention: INVAC-1 (100, 400, and 800 μg) administered intradermally followed by electroporation or by Tropis, a needle-free injection system
Number of subjects: 26
Study 31558479 — intervention group
Group type: EXPERIMENTAL
Intervention: INVAC-1
Number of subjects: 26
Study 31558626 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening by low-dose computed tomography (LDCT)
Number of subjects: 680
Study 31558626 — intervention group
Group type: EXPERIMENTAL
Intervention: QRISK2 score assessment
Number of subjects: 680
Study 31558626 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin primary prevention qualification (QRISK2≥10%)
Number of subjects: 680
Study 31558626 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors of statin use
Number of subjects: 680
Study 31558670 — intervention group
Group type: EXPERIMENTAL
Intervention: ORH-2014 5 mg
Number of subjects: 12
Study 31558670 — intervention group
Group type: EXPERIMENTAL
Intervention: ORH-2014 10 mg
Number of subjects: 12
Study 31558670 — intervention group
Group type: EXPERIMENTAL
Intervention: ORH-2014 15 mg
Number of subjects: 12
Study 31558670 — intervention group
Group type: EXPERIMENTAL
Intervention: ORH-2014
Number of subjects: 12
Study 31558804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) for eight cycles followed by ixazomib maintenance for one year
Number of subjects: 90
Study 31558804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance therapy
Number of subjects: 90
Study 31558804 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate, PFS, and OS
Number of subjects: 90
Study 31558804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 90
Study 31558804 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3/4 toxicities
Number of subjects: 90
Study 31559169 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics strategy combined with clinical assessment (Peabody Developmental Motor Scales, MACS, HAI, AHA, GMFCS)
Number of subjects: 130
Study 31559169 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal and external validation of the radiomics model
Number of subjects: 130
Study 31559605 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese NASH patients
Number of subjects: 84
Study 31559605 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Number of subjects: 84
Study 31560055 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment (oseltamivir)
Number of subjects: 2131
Study 31560055 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior vaccination status
Number of subjects: 2131
Study 31560055 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (1-5 years)
Number of subjects: 2131
Study 31560055 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance mutations
Number of subjects: 2131
Study 31560741 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (150/150/200/10 mg once daily)
Number of subjects: 9
Study 31560741 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF (150/150/200/300 mg once daily)
Number of subjects: 9
Study 31560765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesopic testing
Number of subjects: 36
Study 31560765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-adapted (DA) cyan testing
Number of subjects: 36
Study 31560765 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark-adapted (DA) red testing
Number of subjects: 36
Study 31560765 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a residual outer nuclear layer
Number of subjects: 36
Study 31560935 — intervention group
Group type: EXPERIMENTAL
Intervention: SM08502 (CLK inhibitor), orally administered
Number of subjects: 0
Study 31561030 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implanted in 1.5PP patients
Number of subjects: 3889
Study 31561030 — intervention group
Group type: COMPARATOR
Intervention: 1.5PP patients without ICD
Number of subjects: 3889
Study 31561030 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5PP patients
Number of subjects: 3889